ମୋମେଟାସୋନ

ମୋମେଟାସୋନ
Clinical data
Trade names	Nasonex, Asmanex, Elocon, others
Synonyms	9α,21-Dichloro-11β,17α-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17α-(2-furoate)
AHFS/Drugs.com	monograph
Pregnancy; category	US: C (Risk not ruled out) ; ;
Routes of; administration	Topical, inhalation (nasal spray)
Drug class	Corticosteroid; Glucocorticoid
ATC code	D07AC13 (WHO) R01AD09, R03BA07;
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Bioavailability	Nasal spray is virtually undetectable in plasma; but systemic availability is comparable to fluticasone
Protein binding	98% to 99%
Metabolism	Liver
Elimination half-life	5.8 hours
Identifiers
	IUPAC name (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate;
CAS Number	105102-22-5 ;
PubChem CID	441336;
ChemSpider	390091 ;
UNII	8HR4QJ6DW8;
ChEBI	CHEBI:47564 ;
ChEMBL	CHEMBL1161 ;
ECHA InfoCard	100.125.600
Chemical and physical data
Formula	C22H28Cl2O4 for mometasone; C27H30O6Cl2 as furoate
Molar mass	427.361 g/mol (mometasone); 521.4 g/mol (furoate)
3D model (JSmol)	Interactive image;
	SMILES O=C(O[C@]2(C(=O)CCl)[C@H](C)C[C@H]3[C@@H]4CCC\1=C\C(=O)\C=C/[C@]/1(C)[C@@]4(Cl)[C@@H](O)C[C@]23C)c5occc5;
	InChI InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1 ; Key:WOFMFGQZHJDGCX-ZULDAHANSA-N ;
(what is this?) (verify)

ମୋମେଟାସୋନ (ଇଂରାଜୀ ଭାଷାରେ mometasone, ଅନ୍ୟ ନାମ ମୋମେଟାସୋନ ଫୁରୋଏଟ/mometasone furoate) ଏକ ପ୍ରକାର ଗ୍ଲୁକୋକର୍ଟିକଏଡ (steroid) ଔଷଧ ଯାହା କେତେକ ଚର୍ମ ରୋଗ (skin conditions), ହେ ଫିଭର (hay fever) ଓ ଆଜ୍‌ମା ରୋଗମାନଙ୍କ ଚିକିତ୍ସାରେ ବ୍ୟବ‌ହାର କରାଯାଏ ।^[୩]^[୪]^[୫] ଚିକିତ୍ସା ଅପେକ୍ଷା ଆଜ୍‌ମା ଆକ୍ରମଣର ପ୍ରତିଷେଧ ନିମନ୍ତେ ଏହା ଅଧିକ ବ୍ୟବ‌ହୃତ ହୁଏ ।^[୩] ଏହା ଚର୍ମରେ ଲଗାଯାଏ, ଆଘ୍ରାଣ କରାଯାଏ ଓ ନାକରେ ବ୍ୟବ‌ହାର କରାଯାଇପାରେ ।^[୩]^[୪]^[୫]

ଆଜ୍‌ମା ନିମନ୍ତେ ବ୍ୟବ‌ହାର କଲେ ମୋମେଟାସୋନର ସାଧାରଣ ପ୍ରତିକ୍ରିୟାରେ ମୁଣ୍ଡ ବିନ୍ଧା, ତଣ୍ଟି ଦରଜ ଓ କାଣ୍ଡିଡିଆସିସ (thrush) ହୋଇପାରେ । ^[୩] ନାକରେ ବ୍ୟବ‌ହାର କଲେ ଉର୍ଦ୍ଧ୍ୱ ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ (upper respiratory tract infection) ନାକ ରକ୍ତସ୍ରାବ (nose bleeds) ହୋଇପାରେ ।^[୫] ଚର୍ମରେ ଲଗେଇଲେ ବ୍ରଣ (acne), ଚର୍ମ ଆଟ୍ରୋଫି (skin atrophy) ଓ ଗଲୁ ହୋଇପାରେ ।^[୪] ଏହା ପ୍ରଦାହକୁ (inflammation କମ୍ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୩]

ମୋମେଟାସୋନ ସନ ୧୯୮୧ରେ ପେଟେଣ୍ଟ ହେବା ପରେ ସନ ୧୯୮୭ରେ ଡାକ୍ତରୀ ବ୍ୟବ‌ହାର ନିମନ୍ତେ ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ସ୍ୱୀକୃତ ହୋଇଥିଲା ।^[୬] ଏହା ଜେନେରିକ ଔଷଧ ନାମରେ (generic medication) ବିକ୍ରୟ ହୁଏ ।^[୭] ସନ ୨୦୧୯ରେ ସଂଯୁକ୍ତ ରାଷ୍ଟ୍ରରେ (United Kingdom) ଏନଏଚଏସକୁ (NHS) ଏହାର ଏକ ମାସର ଡୋଜ ପିଛା ପ୍ରାୟ ୩୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ କରିବାକୁ ପଡ଼ୁଥିଲା ।^[୭] ସନ ୨୦୧୬ରେ ଏହାର ୩ ନିୟୁତରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ ହୋଇ ସର୍ବାଧିକ ପ୍ରେସକ୍ରିସନ ତାଲିକାର ୧୬୫ତମ ସ୍ଥାନରେ ଥଲା ।^[୮]

ଆଧାର

↑ "International brands for Mometasone". Drugs.com. Retrieved 17 November 2016.
↑ Zia R. Tayab; Tom C. Fardon; Daniel K. C. Lee; Kay Haggart; Lesley C. McFarlane; Brian J. Lipworth; Günther Hochhaus (November 2007). "Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate". Br J Clin Pharmacol. 64 (5): 698–705. doi:10.1111/j.1365-2125.2007.02919.x. PMC 2203259. PMID 17509041. {{cite journal}}: Unknown parameter |last-author-amp= ignored (|name-list-style= suggested) (help)
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "Mometasone Furoate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 11 March 2019.
↑ ^୪.୦ ^୪.୧ ^୪.୨ "Mometasone Furoate topical Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 11 March 2019.
↑ ^୫.୦ ^୫.୧ ^୫.୨ "Mometasone Furoate eent Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 11 March 2019.
↑ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 488. ISBN 9783527607495.
↑ ^୭.୦ ^୭.୧ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 265. ISBN 9780857113382.
↑ "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.

ବାହ୍ୟ ଲିଙ୍କ

Drug Information from the NIH

[brands2016-1] "International brands for Mometasone". Drugs.com. Retrieved 17 November 2016.

[2] Zia R. Tayab; Tom C. Fardon; Daniel K. C. Lee; Kay Haggart; Lesley C. McFarlane; Brian J. Lipworth; Günther Hochhaus (November 2007). "Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate". Br J Clin Pharmacol. 64 (5): 698–705. doi:10.1111/j.1365-2125.2007.02919.x. PMC 2203259. PMID 17509041. {{cite journal}}: Unknown parameter |last-author-amp= ignored (|name-list-style= suggested) (help)

[AHFS2019Asthma-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "Mometasone Furoate Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 11 March 2019.

[AHFS2019Skin-4] ୪.୦ ^୪.୧ ^୪.୨ "Mometasone Furoate topical Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 11 March 2019.

[AHFS2019Nose-5] ୫.୦ ^୫.୧ ^୫.୨ "Mometasone Furoate eent Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 11 March 2019.

[Fis2006-6] Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 488. ISBN 9783527607495.

[BNF76-7] ୭.୦ ^୭.୧ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 265. ISBN 9780857113382.

[8] "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.

[୩]

[୪]

[୫]

[୧]

[୨]

[୬]

[୭]

[୮]

Clinical data


Trade names	Nasonex, Asmanex, Elocon, others^[୧]
Synonyms	9α,21-Dichloro-11β,17α-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17α-(2-furoate)
AHFS/Drugs.com	monograph
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Topical, inhalation (nasal spray)
Drug class	Corticosteroid; Glucocorticoid
ATC code	D07AC13 (WHO) R01AD09, R03BA07
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	Nasal spray is virtually undetectable in plasma; but systemic availability is comparable to fluticasone^[୨]
Protein binding	98% to 99%
Metabolism	Liver
Elimination half-life	5.8 hours
Identifiers
IUPAC name (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
CAS Number	105102-22-5^Y
PubChem CID	441336
ChemSpider	390091^Y
UNII	8HR4QJ6DW8
ChEBI	CHEBI:47564^Y
ChEMBL	CHEMBL1161^Y
ECHA InfoCard	100.125.600
Chemical and physical data
Formula	C₂₂H₂₈Cl₂O₄ for mometasone C₂₇H₃₀O₆Cl₂ as furoate
Molar mass	427.361 g/mol (mometasone) 521.4 g/mol (furoate)
3D model (JSmol)	Interactive image
SMILES O=C(O[C@]2(C(=O)CCl)[C@H](C)C[C@H]3[C@@H]4CCC\1=C\C(=O)\C=C/[C@]/1(C)[C@@]4(Cl)[C@@H](O)C[C@]23C)c5occc5
InChI InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1^Y Key:WOFMFGQZHJDGCX-ZULDAHANSA-N^Y
^NY (what is this?) (verify)